Tag:

Eisai

Latest Headlines

Latest Headlines

Eisai rejig means sales-force downsizing at a critical moment for Arena's Belviq

Less than a year ago, Arena marketing partner Eisai pledged to add another 200 staffers to its rep army for obesity therapy Belviq, bringing the total force to 600. Now, though, the Japanese pharma is doing some stateside job-trimming, and the restructuring will affect Arena's med, too.

Japan's Eisai cuts 25% of U.S. commercial, services units

Japan's Eisai has decided to follow the cost-cutting trend of many of its multinational counterparts and lay off a quarter of its U.S. commercial and regional corporate services units, which currently employ about 850 people. The unit said the 200-plus staff reductions would not affect manufacturing or R&D units.

UPDATED: Struggling Eisai will slash 200-plus U.S. jobs as sales revenue slides

Japan's Eisai is taking out the budget ax and chopping more than 200 jobs out of its U.S. operations. A spokesperson for the company tells FierceBiotech tonight that the cuts will center on Eisai's commercial and regional corporate services units, which employ about 850 people. She adds: "The restructuring will not affect our manufacturing or R&D units."

UPDATED: Eisai to shed 200-plus jobs as it pares down U.S. workforce

Just a couple of weeks after fellow Japanese drugmaker Daiichi Sankyo announced a layoffs drive as part of a U.S. revamp, Eisai is doing the same. Two of its units in the country are headed for a 25% shrinkage, the company said Thursday.

Eisai gets EMA nod for Lenvima just weeks after FDA approval

Eisai has gotten its second dose of good news in as many months. Weeks after getting an FDA approval for its thyroid cancer drug Lenvima, the struggling Japanese drugmaker has gotten the nod for the potential blockbuster by the European Medicines Agency (EMA).

Japan's Eisai receives $40M in revised cancer therapy deal with Epizyme

Japan's Eisai sold the worldwide rights, excluding Japan, to Phase I/II cancer candidate EP-6438 to U.S.-based Epizyme for $40 million upfront, revising a 2011 agreement on discovery, development and commercialization of a therapy aimed at non-Hodgkin B-cell lymphoma and other cancers.

Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object

Eisai won speedy FDA approval for its new cancer drug Lenvima, eyeing $1 billion in potential sales and setting the stage for a showdown with Bayer's cancer-fighter Nexavar.

Eisai nabs quick FDA blessing for cancer blockbuster hopeful Lenvima

Eisai grabbed an early green light on Friday from U.S. regulators for thyroid cancer drug Lenvima, meaning the Japanese pharma can now get an earlier-than-expected start on trying to make its blockbuster dreams a reality.

Eisai wins an early FDA nod for its self-described cancer blockbuster

Eisai is counting on its new cancer drug to eventually bring in more than $1 billion a year, and now, thanks to an early FDA approval, the Japanese drugmaker has a head start on making that a reality.

Eisai says its new thyroid cancer drug is a sure blockbuster

Eisai, on the mend after some big patent losses, believes its top prospect in oncology can bring in peak annual sales north of $1 billion, beginning with thyroid cancer and expanding to treat other tumor types.